Billiontoone (NASDAQ:BLLN) Research Coverage Started at BTIG Research

BTIG Research started coverage on shares of Billiontoone (NASDAQ:BLLN) in a report published on Monday, MarketBeat reports. The brokerage issued a buy rating and a $160.00 target price on the stock.

Several other research firms also recently weighed in on BLLN. Jefferies Financial Group assumed coverage on Billiontoone in a research report on Monday. They set a “hold” rating and a $117.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of Billiontoone in a research report on Monday. They set an “overweight” rating and a $150.00 price objective on the stock. Wells Fargo & Company started coverage on shares of Billiontoone in a research note on Monday. They issued an “equal weight” rating and a $110.00 target price on the stock. William Blair began coverage on shares of Billiontoone in a research note on Monday. They set an “outperform” rating for the company. Finally, Stifel Nicolaus began coverage on shares of Billiontoone in a report on Monday. They set a “buy” rating and a $145.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $138.67.

Billiontoone Trading Down 10.6%

Shares of NASDAQ BLLN opened at $102.76 on Monday. Billiontoone has a 1-year low of $88.00 and a 1-year high of $138.70.

Billiontoone Company Profile

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.